| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
52,851 |
38,663 |
$4.50M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,918 |
15,542 |
$1.37M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
20,060 |
14,657 |
$830K |
| 62323 |
|
294 |
231 |
$51K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
245 |
201 |
$38K |
| 20611 |
|
542 |
382 |
$38K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,184 |
1,088 |
$25K |
| 64493 |
|
71 |
53 |
$11K |
| 20553 |
|
216 |
154 |
$11K |
| 99152 |
|
289 |
192 |
$10K |
| 64635 |
|
21 |
15 |
$8K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
655 |
525 |
$7K |
| 99215 |
Prolong outpt/office vis |
57 |
39 |
$7K |
| 81025 |
|
878 |
805 |
$7K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
195 |
160 |
$5K |
| 27096 |
|
34 |
25 |
$5K |
| 76942 |
|
87 |
70 |
$5K |
| 62369 |
|
112 |
90 |
$4K |
| 64636 |
|
25 |
14 |
$4K |
| 64483 |
|
19 |
13 |
$4K |
| 64494 |
|
42 |
29 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,359 |
797 |
$3K |
| 96132 |
|
149 |
78 |
$3K |
| 96130 |
|
149 |
78 |
$2K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
479 |
334 |
$2K |
| 76882 |
|
30 |
26 |
$2K |
| 20610 |
|
50 |
25 |
$1K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
271 |
181 |
$1K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
2,021 |
1,560 |
$1K |
| 99153 |
Mod sedat endo service >5yrs |
88 |
51 |
$812.63 |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
265 |
194 |
$721.53 |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
149 |
78 |
$679.63 |
| 64450 |
|
14 |
13 |
$661.38 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
17 |
15 |
$580.17 |
| 96138 |
|
149 |
78 |
$547.50 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
199 |
105 |
$437.41 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
789 |
518 |
$281.59 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
220 |
150 |
$111.25 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
194 |
126 |
$64.68 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
690 |
464 |
$16.31 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,101 |
549 |
$3.97 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
143 |
75 |
$0.46 |
| 36415 |
Collection of venous blood by venipuncture |
84 |
82 |
$0.00 |
| 99156 |
|
29 |
16 |
$0.00 |
| A4550 |
Surgical trays |
110 |
80 |
$0.00 |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
561 |
278 |
$0.00 |